Immunotherapy for Guillain-Barré syndrome
10.3760/cma.j.cn115354-20210520-00325
- VernacularTitle:吉兰-巴雷综合征的免疫治疗
- Author:
Yawei GU
1
;
Xu CHU
;
Lan ZHAO
;
Lijun WANG
;
Hongxin WANG
Author Information
1. 南开大学附属第四中心医院神经内科，天津 300140
- Keywords:
Guillain-Barré syndrome;
Immunotherapy;
Monoclonal antibody;
Immunomodulator;
Cytokine
- From:
Chinese Journal of Neuromedicine
2022;21(2):207-210
- CountryChina
- Language:Chinese
-
Abstract:
The first line of clinical treatment for Guillain-Barré Syndrome (GBS) is intravenous immunoglobulin (IVIg) and plasma exchange (PE). However, the prognoses of patients vary greatly, with high disability and mortality rates. Immunotherapy has become a research hotspot in recent years. This paper reviews the research progress of GBS immunotherapy in recent years from the prospect of monoclonal antibody, immunomodulator and cytokines, in order to provide basis for treatment of GBS.
